Between two kingdoms (CAR-T and hematopoietic stem cell transplantation)

Reading through the longitudinal patient report outcomes (PRO) with chimeric antigen T-cell (CAR-T) by Sidena et al. [1] evokes a memory of a recent lymphoma patient who suffered disease progression following an autologous stem cell transplant (AutoSCT). He subsequently received a CAR-T. He suggested a book that could best explain his feelings subsequent to post-transplant progression and then being given hope for another chance, "between two kingdoms."